PDS Biotechnology(PDSB) ZACKS·2024-10-22 17:06Core Viewpoint - PDS Biotechnology (PDSB) has received a Zacks Rank 1 (Strong Buy) upgrade, indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][2]. Earnings Outlook - The Zacks rating upgrade reflects optimism regarding PDS Biotechnology's earnings outlook, which is expected to create buying pressure and potentially increase its stock price [2]. - For the fiscal year ending December 2024, PDS Biotechnology is projected to earn -$1.24 per share, representing a 10.8% change from the previous year's reported figure [5]. Earnings Estimate Revisions - Analysts have consistently raised their earnings estimates for PDS Biotechnology, with the Zacks Consensus Estimate increasing by 15.4% over the past three months [5]. - The correlation between earnings estimate revisions and near-term stock movements is strong, suggesting that tracking these revisions can be beneficial for investment decisions [4]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [4]. - PDS Biotechnology's upgrade to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [6].